An interventional study of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan in Healthy Volunteer and Malaria, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 54 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Malaria by National Institute of Allergy and Infectious Diseases (NIAID) — 9 open to participants now, 11 under way, none of them phase 3. Malaria · National Institute of Allergy and Infectious Diseases (NIAID).
Among the 112 studies in Malaria by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 49th largest by planned enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 with no phase, and was the 111th registered.
1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →9 of the 112 studies in Malaria by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 2 countries. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–54 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in Mali
Ages 15–49 · Women only · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–70 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–50 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in Mali
Ages 15–25 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 54 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 13 · Phase 3 3 · Phase 4 2
First in 1998; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 252 across 939 interventional studies indexed under Malaria.
Median enrollment 90 across the 63 interventional studies, 508 across the 48 observational. Of the 96 that completed or were terminated, 19 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
1 of the studies in Malaria by National Institute of Allergy and Infectious Diseases (NIAID) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607003National Institute of Allergy and Infectious Diseases (NIAID)Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays | 2027-11-26 |
Add it to your calendar (.ics) → With an account.
Among the 112 studies in Malaria by National Institute of Allergy and Infectious Diseases (NIAID), from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Malaria is a serious disease caused by parasites spread by mosquitoes. To better diagnose and treat malaria, researchers need to learn more about where the parasites go when they enter a person's body. They want to see if they can locate the malaria parasites in the body using imaging scans.
Objective:
To learn whether imaging scans can locate parasites in people with malaria.
Eligibility:
Healthy people aged 18 to 54 years. They must be enrolled in protocol IRB001970 or IRB002627 for controlled malaria infection.
Design:
Participants will be screened. They will have blood drawn and a physical exam, including an abdominal exam to check the size of their spleen.
Participants for this study will have 2 or 3 positron emission tomography/computed tomography (PET/CT) scans: The first will be about 3 days before they are deliberately infected with malaria for a different study. The second will be about 13 days later, while they have the disease. The third scan is optional; it will be done about 3 and 1/2 weeks after the second scan.
For each scan, participants will receive a radioactive tracer called fluorodeoxyglucose (FDG). FDG will be injected through a tube inserted into a vein. They will lie on a table that slides through a doughnut-shaped machine. PET/CT uses x-rays to create images of the inside of the body.
All participants will have a follow-up visit about 3 and 1/2 weeks after the second scan. The blood draw and physical exam will be repeated. This visit may be combined with the third scan for those who choose it.
Study Description:
Participants who are enrolled in a Plasmodium vivax challenge model protocol at the NIH Clinical Center (CC) may be co-enrolled in this single-site study to undergo a 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) scan of their chest, abdomen, and pelvis at baseline before controlled human malaria infection (CHMI) inoculation and again at the expected time of peak parasitemia. FDG uptake will be used to visualize organ-specific changes as a result of malaria infection. Other assessments will include inflammatory labs, signs of bone marrow activation, compete blood count (CBC), reticulocyte counts, and transcriptional analysis.
Objectives:
Primary Objectives:
-To measure changes in spleen standardized uptake value (SUV) from baseline in participants undergoing P. vivax CHMI using PET/CT imaging
Secondary Objectives:
Exploratory Objectives:
Endpoints:
Primary Endpoint:
-Percentage change in mean spleen SUV from baseline to post CHMI
Key Secondary Endpoints:
Additional Secondary Endpoints:
Exploratory Endpoints:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Individuals of must agree to use an acceptable method of from 1 month prior to the first FDG-PET/CT scan through the end of the study. Participants will also be expected to adhere to the strictest of the contraception
requirements of any studies they are co-enrolled in. Acceptable methods of contraception include the following:
Participants who otherwise are not at risk of becoming pregnant, at the judgement of the investigator will not be required to use contraception. Such participants may include those:
EXCLUSION CRITERIA
An individual who meets any of the following criteria will be excluded from participation in this study:
participating in the study.
Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on the LMIV CHMI trials described above and NIH protocol 17I0122, NIAID Centralized Sequencing Protocol. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the principal investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy Volunteers are co-enrolled in a Plasmodium vivax challenge model protocol at the NIH Clinical Center.
Diagnostic Test: 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan
Participants are co-enrolled in a Plasmodium vivax challenge model protocol at the NIH Clinical Center. These participants will undergo up to 3 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) scans of their chest, abdomen, and pelvis. PET/CT scans will occur at baseline (before controlled human malaria infection (CHMI) inoculation), and at the expected time of peak parasitemia. Participants may have an optional 3rd PET/CT scan at day 34 after the CHMI inoculation. FDG uptake will be used to visualize organ-specific changes as a result of malaria infection.
To measure changes in spleen standardized uptake value (SUV) from baseline in participants undergoing P. vivax CHMI using PET/CT imaging
Percentage change in mean spleen SUV from baseline to post-CHMI
Time frame: 34 (+/- 5 days) days post CHMI Inoculation
To measure changes in organ specific uptake of FDG from baseline in participants undergoing P. vivax CHMI using PET/CT imaging
Percentage change in max spleen SUV Percentage change in peak spleen SUVPercentage change in spleen volume Percentage change in liver volumePercentage change in liver SUVPercentage change in bone marrow SUV
Time frame: 34 (+/- 5 days) days post CHMI Inoculation
Explore the relationship between dyserythropoiesis, hematological abnormalities, and bone marrow/splenic involvement in acute P. vivax malaria.
CBC with differential, reticulocyte count, and erythropoietin (EPO) at baseline, at the time of the second FDG-PET/CT, and at the end of the CHMI-related activities performed under the co-enrolled study.
Time frame: 34 (+/- 5 days) days post CHMI Inoculation
Plan to share: Undecided
Start is estimated for Nov 2026; primary completion for Nov 2030, 47 months later.
Of 96 non-industry interventional studies with no phase under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 47 months is above that.
Counting every sponsor, half of 102 studies reached it within 23 months; a quarter within 8 and three quarters within 33.
Start moved 31 times since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, last on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Allergy and Infectious Diseases (NIAID) →